| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 12, 2026, David Moatazedi, a member of the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”), communicated to the Board that he has determined not to stand for re-election to the Board at the Company’s 2026 A... |
| 26 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SECURITIES Purchase Agreement (this “Agreement”) is dated as of August 20, 2026, by and between Biomerica, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 04 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 29, 2026 (the “Effective Date”), is entered into between Biomerica, Inc., a Delaware corporation (the “Seller”), and each of the persons listed on Exhibit A hereto (e... |
| 16 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Biomerica, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) on December 12, 2025. As of October 15, 2025, the record date for the 2025 Annual Meeting, the Company had 2,947,966 shares of commo... |
| 08 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
IRVINE, CA – October 8, 2025 – Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings deca... |
| 06 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Mr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts |
| 16 Apr 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Shares Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025 |
| 17 Dec 2024 |
8-K: Submission of Matters to a Vote of Security Holders
Biomerica, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on December 13, 2024, at its corporate headquarters in Irvine, California. As of October 16, 2024, the record date for the 2024 Annu... |
| 06 Nov 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on May 7, 2024, Biomerica, Inc. (the “Company” or “Biomerica”) received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the clos... |
| 28 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 26, 2024, Mr. Jack Kenny notified Biomerica, Inc. (the “Company”) of his resignation as a member of the board of directors of the Company (the “Board”) and all committees thereof, and as the Company’s Chairman of the Board, effec... |
| 10 May 2024 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule
Biomerica, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EF Hutton LLC and R. F. Lafferty & Co., Inc. (each individually, a “Sales Agent” and together, the “Sales Agents”) as follows: |
| 11 Dec 2023 |
8-K: Submission of Matters to a Vote of Security Holders
Biomerica, Inc. (the “Company”) held its 2023 annual meeting (the “2023 Annual Meeting”) of stockholders of the Company on December 7, 2023, at its corporate headquarter in Irvine, California. As of October 14, 2023, the record date for ... |
| 19 Sep 2023 |
8-K: Regulation FD Disclosure
On Sep 15, 2023 the company submitted to the FDA the final H. pylori data-set requested by the FDA during the FDA’s recent review of the 510-K filed by the Company. The Company received confirmation from the FDA that the data was receive... |
| 28 Aug 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
Kenny has a proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian Bioscience |
| 26 Jul 2023 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global. |
| 25 Apr 2023 |
8-K: Regulation FD Disclosure
On April 25, 2023, Biomerica, Inc. (“the “Company”) presented an investor presentation to the investment community. The updated investor presentation includes slides pertaining to the Company’s new relationship with Gastro Health, the le... |
| 07 Mar 2023 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
As the Representative of the Several underwriters, if any, named in Schedule I hereto |
| 02 Mar 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective March 1, 2023, the Board of Directors of Biomerica, Inc. (the “Company”) appointed Gary Lu as its Chief Financial Officer, principal financial officer and principal accounting officer. Mr. Lu, age 42, previously served as the C... |
| 07 Feb 2023 |
8-K: Regulation FD Disclosure
On February 6, 2023, Biomerica, Inc. (“the “Company”) presented an investor presentation to the investment community. The investor presentation is attached hereto as Exhibit 99.1. |
| 16 Dec 2022 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 16, 2022, the Board of Directors of Biomerica, Inc. (the “Company”) unanimously approved a modification to the 2022 Incentive Stock Plan (the “Plan”) to (i) remove the Board’s ability to amend the exercise price of outstandin... |
Loading...